Eylea (Aflibercept)

Eylea is an FDA cleared treatment for Neovascular or Wet AMD, Retinal Vein Occlusions, and Diabetic Retinopathy.

Wet AMD is a type of Advanced Age Related Macular Degeneration in which patients loose vision quickly due to leakage or bleeding from abnormal blood vessels growing beneath the retina. Patients treated with Eylea have a 95% chance of maintaining their vision over two years and a 40% chance of doubling their vision with treatment. 

Retinal Vein Occlusion is a condition in which the retinal veins are blocked, and fluid build up in the center of the retina.  This is called macular edema, and can cause blurred vision, distortion and eventually lead to permanent vision loss. 

Diabetic Retinopathy is a  condition where patients with diabetes loose vision due to swelling of the center of the retina (Macular Edema) or from abnormal blood vessels in the retina that bleed or cause retinal detachments. Eylea has been shown to work better than Avastin and Lucentis in Diabetic retinopathy.

If you or someone you know would like more information on Eylea, please contact us for an appointment.